Fig. 1From: Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapyPatient flow. Note: One of the adverse events (AEs) leading to withdrawal during Cycle 1 in the RGB-02 arm resulted in death after patient withdrawalBack to article page